We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SEPRACOR REPORTS PRELIMINARY PHASE II STUDY RESULTS FOR SEP-225441 FOR THE TREATMENT OF GENERALIZED ANXIETY DISORDER.
- Abstract
The article reports on the completion of the preliminary results of a Phase II study of Sepracor Inc. on SEP-225441 as treatment of generalized anxiety disorder (GAD). Sepracor has annunciated the culmination of the analysis and validation of its Phase II study on the efficacy and safety of SEP-225441, a modified release formulation of eszopiclone to treat GAD. The company has disclosed its disappointment of the study findings, as the study did not meet its primary efficacy endpoint.
- Subjects
CLINICAL trials; DRUG efficacy; MEDICAL research; SEPRACOR Inc.; ANXIETY disorders treatment; PHARMACEUTICAL research; NEUROSES; THERAPEUTICS
- Publication
Psychiatry (1550-5952), 2009, Vol 6, Issue 3, p13
- ISSN
1550-5952
- Publication type
Article